NAFDAC alerts public on G fuel energy drinks

0
178
NAFDAC alerts public on G fuel energy drinks
NAFDAC alerts public on G fuel energy drinks

The National Agency for Food and Drugs Administration and Control (NAFDAC) has informed the public about the recall of G Fuel brand Energy Drinks by T&E Imports and GPAE Trading Corp due to their high caffeine content.

This notification is detailed in public alert No. 034/2023, which was released to the media in Abuja on Thursday by NAFDAC Director-General, Prof Mojisola Adeyeye.

Adeyeye revealed that NAFDAC had been made aware of the product recall by the Netherlands Food and Consumer Product Safety Authority and the Canadian Food Inspection Agency.

She stressed that the consumption of products containing elevated levels of caffeine can lead to adverse effects such as headaches, insomnia, irritability, and nervousness.

Even individuals with low sensitivity to caffeine can experience these effects at relatively low consumption levels.

Pregnant women, in particular, were cautioned against using these products, as excessive caffeine intake may heighten the risk of miscarriage and contribute to low birth weight.

Adeyeye pointed out that the affected products lack cautionary statements limiting the daily serving intake, and they are typically sold online. Notably, these products are not registered with NAFDAC.

The agency strongly urged both consumers and retailers to abstain from using, selling, serving, or distributing the implicated G Fuel Energy Drinks.

NAFDAC encourages the public to report any suspicions regarding the distribution and sale of substandard packaged food products to the nearest NAFDAC office.

NAFDAC can be reached via phone at 0800-162-3322 or through email at sf.alert@nafdac.gov.ng. Healthcare professionals and patients are also urged to report any adverse events or side effects related to the use of NAFDAC-regulated products.

Various reporting platforms are available, including the NAFDAC website (www.nafdac.gov.ng), the Med-safety application for Android and iOS devices, and via email at pharmacovigilance@nafdac.gov.ng.